This week's roundup of Houston innovators includes Robert Kester of Honeywell Rebellion, Serafina Lalany of Houston Exponential, and Shaun Noorian of Empower Pharmacy. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from oil and gas tech to pharmaceuticals — recently making headlines in Houston innovation.

Robert Kester, president and general manager at Honeywell Rebellion

Robert Kester, founder of Rebellion Photonics and president and general manager at Honeywell

Robert Kester joins the Houston Innovators Podcast to discuss his entrepreneurial journey. Photo courtesy of Honeywell

Robert Kester co-founded Rebellion Photonics in 2010. After several years of developing the device that could be used to automate the process and improve safety on oil and gas sites, Kester and his team saw a rising need for the tech — which also meant a need for Rebellion to scale quickly. In 2019, Rebellion exited in an acquisition by Honeywell.

"For us it just made sense that we could team up with Honeywell and figure out how we could scale this thing globally and quickly, so that we could help be a solution for climate change," Kester continues.

Now, as president and general manager at Honeywell Rebellion, Kester still works on his technology under the umbrella of the Honeywell brand. He joined the Houston Innovators Podcast last week to discuss the transition and what he's focused on now. Click here to read more and stream the episode.

Serafina Lalany, interim president of Houston Exponential

Serafina Lalany, vice president of operations at Houston Exponential

Last week, Serafina Lalany is acting as interim identifies the organization's new leader. Photo courtesy of Serafina Lalany

Serafina Lalany, vice president of operations at Houston Exponential, will act as interim executive director for the organization after Harvin Moore, who has served as president of HX since June 2019, announced his resignation last week. HX's Chair Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, says Moore is resigning to devote more time to working with growth-stage companies as a mentor, adviser, and investor.

"In a rapidly growing and evolving landscape like this one, we must ensure resources are leveraged for greatest impact," Burger says. "The HX executive committee believes now is an appropriate time re-strategize with the HX organization to ensure it is aligned with the current needs of the innovation ecosystem. While changes may be called for to place resources where they can do the most good, there remains a need for a broad ecosystem champion and HX will continue to serve in that role." Click here to read more.

Shaun Noorian, founder and CEO of Empower Pharmacy

Houston founder talks growth and innovation in the pharmaceuticals industryShaun Noorian, founder and CEO of Empower Pharmacy, joined InnovationMap for a Q&A on his rapidly growing compounding pharmacy business. Photo courtesy of Empower Pharmacy

Shaun Noorian founded Empower Pharmacy so he could create a business that was service focused, and now the company has grown and expanded — and is now working on building two new 85,000-square-foot facilities in Houston. Noorian, in a Q&A with InnovationMap, explained that Houston has been integral to his success.

"I think being in Houston is one of the reasons why we've grown to become the largest compounding pharmacy in the nation," Noorian tells InnovationMap. "I'm sure we're all aware that having the largest medical center in the world in your own backyard is a great way to have more prescribers than pretty much any other city in the country. That definitely helped us and continues to help us grow.

"Additionally, being the third largest city by population means we have a large workforce to pull a diverse workforce for whatever this company needs," he continues. "Having a diverse workforce has been integral in our growth." Click here to read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.